Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 12/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138241 | 0.91 | NR3C1 (0.70) | NR3C1ALDH1A1NPSR1HTTMEN1 | |
| SCHEMBL4147688 | 0.85 | NR3C1 (1.00) | NR3C1ALDH1A1NPSR1HTTMEN1 | |
| SCHEMBL4142829 | 0.82 | NR3C1 (1.00) | NR3C1ALDH1A1NPSR1HTTMEN1 | |
| SCHEMBL4135159 | 0.82 | NR3C1 (0.77) | NR3C1ALDH1A1NPSR1HTTMEN1 | |
| SCHEMBL4151237 | 0.80 | NR3C1 (0.89) | NR3C1ALDH1A1NPSR1HTTMEN1 | |
| SCHEMBL4143694 | 0.80 | NR3C1 (1.00) | NR3C1ALDH1A1NPSR1HTTMEN1 | |
| SCHEMBL4143690 | 0.79 | NR3C1 (0.88) | NR3C1ALDH1A1NPSR1HTTMEN1 | |
| SCHEMBL4142904 | 0.78 | NR3C1 (0.84) | NR3C1ALDH1A1NPSR1HTTMEN1 | |
| SCHEMBL4142900 | 0.77 | NR3C1 (0.82) | NR3C1ALDH1A1NPSR1HTTMEN1 | |
| SCHEMBL4151246 | 0.75 | NR3C1 (0.73) | NR3C1ALDH1A1NPSR1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173664-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173664-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7576076-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576076-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, TYMS | NR3C1 1/4885ALDH1A1 3275/4885NPSR1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.